Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nephropathy
Biotech
Analysts hail Vera's kidney drug as potential 'functional cure'
The durability of the effects seen in the phase 2b trial led Evercore ISI analysts to say “this feels like a ‘functional cure.'”
Nick Paul Taylor
Oct 28, 2024 9:27am
Vertex pays $4.9 billion to hike Alpine’s immunology trail
Apr 10, 2024 5:30pm
Novartis' $3.2B Chinook bet takes flight as phase 3 hits goal
Oct 30, 2023 8:16am
Omeros stops kidney disease phase 3 after interim review fail
Oct 16, 2023 8:45am
Alnylam culls 3 programs, including once-touted nephropathy med
Dec 16, 2022 1:52pm
